Back to results
US 9,284,611 B2Granted
Epigenetic biomarker ZNF545 for diagnosing and prognosis of gastric cancer
AssigneeThe Chinese University of Hong Kong
InventorsJun Yu, Joseph Jao Yiu Sung
Life of this patent
Estimating the term…
Abstract
The present invention provides a method for diagnosing and determining prognosis of gastric cancer in a subject by detecting suppressed expression of the ZNF545 gene, which in some cases is due to elevated methylation level in the genomic sequence of this gene. A kit and device useful for such a method are also provided. In addition, the present invention provides a method for treating gastric cancer by increasing ZNF545 gene expression or activity.
Claims5
A method for assessing time of survival from gastric cancer in a subject suffering from gastric cancer, comprising the steps of:
- (a) detecting methylation in a promoter region of the ZNF545 gene corresponding to SEQ ID NO:
- 1 or 2 by:
- (i) treating genomic DNA of a sample taken from the subject with a bisulfite, wherein the sample is taken from non-cancer tissue adjacent to the gastric cancer;
- (ii) amplifying the treated genomic DNA by performing a polymerase chain reaction (PCR) with a primer selected from the group consisting of SEQ ID NOs:
- 12, 13, 16, and 17;
- (iii) detecting in the amplified DNA after stop (b) a methylated version of the promoter region of the ZNF545 gene;
- and
- (b) determining the subject as having a shorter time of survival when a methylated version of the genomic DNA sequence is detected in the sample, in comparison to another subject suffering from gastric cancer but whose non-cancer tissue adjacent to gastric cancer is determined to contain no methylated version of the promoter region of the ZNF545 gene.
5 more elements
Dependencies are inferred from the claim text.